BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24944485)

  • 1. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
    Chung KH; Lee DH; Jin E; Cho Y; Seo JY; Kim N; Jeong SH; Kim JW; Hwang JH; Shin CM
    Gut Liver; 2014 Nov; 8(6):605-11. PubMed ID: 25368747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2017 Aug; 70(2):72-80. PubMed ID: 28830132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Apr; 21(16):5032-8. PubMed ID: 25945019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
    Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
    Lee ST; Lee DH; Lim JH; Kim N; Park YS; Shin CM; Jo HJ; Song IS
    Gut Liver; 2015 Jul; 9(4):478-85. PubMed ID: 25071068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
    Kim SE; Roh JH; Park MI; Park SJ; Moon W; Kim JH; Jung K; Heo JJ
    Korean J Gastroenterol; 2019 Jan; 73(1):26-34. PubMed ID: 30690955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
    Yoon H; Kim N; Kim JY; Park SY; Park JH; Jung HC; Song IS
    J Gastroenterol Hepatol; 2011 Jan; 26(1):44-8. PubMed ID: 21175792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
    Rakici H; Akdoğan RA; Bedir R; Copur A; Yilmaz A
    J Dig Dis; 2014 Sep; 15(9):508-13. PubMed ID: 24980811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
    Bago J; Pevec B; Tomić M; Marusić M; Bakula V; Bago P
    Wien Klin Wochenschr; 2009; 121(1-2):47-52. PubMed ID: 19263014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
    Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
    Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
    Marušić M; Dominković L; Majstorović Barać K; Gulić S; Bago J; Pezerović D
    Minerva Gastroenterol Dietol; 2017 Jun; 63(2):80-84. PubMed ID: 27973462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line bismuth-containing quadruple therapy for
    Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
    World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.